# US 2025/0082732 A1 · Anti-microbial and anti-inflammatory compositions and methods for treating enteric diseases in animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082732 A1
- Document ID: US20250082732A1
- Status: Published application
- Kind: A1
- Application number: 18/793,255
- Filed: 2024-08-02
- Published: 2025-03-13
- Earliest claimed: 2019-01-04
- Assignees: Vets Plus, Inc.
- Applicants: Vets Plus, Inc.
- Inventors: Daniel J. DuBourdieu; Rajiv Lall; Ajay Srivastava; Jamil Talukder
- Web page: https://patentgrep.com/patent/US20250082732A1

## CPC

- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/12: Ketones
- A61K 31/722: Chitin, chitosan
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 36/67: Piperaceae (Pepper family), e.g. Jamaican pepper or kava
- A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K 36/88: Liliopsida (monocotyledons)
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 36/9068: Zingiber, e.g. garden ginger
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is a composition intended for consumption by animals containing antimicrobials and anti-inflammatory agents, which may include ovotransferrin, chitosan, and curcumin. The composition may be provided as powder that is mixed into feeds, may be incorporated into pellets, or may be delivered through water, among other methods of dosage. The invention is intended as a health supplement for increased gain and improved general health in production animals affected by enteric diseases such as coccidiosis and as a general health supplement in humans and companion animals facing enteric diseases to maintain the gut microbiome.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

An oral ingestible composition comprising an iron-binding glycoprotein and chitosan.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the oral ingestible composition is in the form of a dough, a paste, a gel, a powder, a liquid, and a tablet.

### Claim 23 (depends on 21)

The composition of claim 21, wherein the oral ingestible composition is in the form of a dough.

### Claim 24 (depends on 21)

The composition of claim 21, wherein the oral ingestible composition is in the form of a gel.

### Claim 25 (depends on 21)

The composition of claim 21, wherein:
the iron-binding glycoprotein is present in the oral ingestible composition in an amount of at least 0.01% by weight of the oral ingestible composition and up to 2% by weight of the oral ingestible composition; and
the chitosan is present in the oral ingestible composition in an amount of at least 0.05% by weight of the oral ingestible composition and up to 8% by weight of the oral ingestible composition.

### Claim 26 (depends on 21)

The composition of claim 21, wherein:
the iron-binding glycoprotein is present in the oral ingestible composition in an amount of at least 0.05% by weight of the oral ingestible composition and up to 1% by weight of the oral ingestible composition; and
chitosan, wherein the chitosan is present in the oral ingestible composition in an amount of at least 0.1% by weight of the oral ingestible composition and up to 4% by weight of the oral ingestible composition.

### Claim 27 (depends on 21)

The composition of claim 21, wherein:
the iron-binding glycoprotein is present in the oral ingestible composition in an amount of at least 0.05% by weight of the oral ingestible composition and up to 0.5% by weight of the oral ingestible composition; and
chitosan, wherein the chitosan is present in the oral ingestible composition in an amount of at least 0.1% by weight of the oral ingestible composition and up to 2% by weight of the oral ingestible composition.

### Claim 28 (depends on 21)

The composition of claim 21, wherein the iron-binding glycoprotein and the chitosan are present in the oral ingestible composition in a weight ratio of from about 1:1 (iron-binding glycoprotein:chitosan) to about 2:7 (iron-binding glycoprotein:chitosan).

### Claim 29 (depends on 21)

The composition of claim 21, wherein the iron-binding glycoprotein is ovotransferrin.

### Claim 30 (depends on 21)

The composition of claim 21, wherein the chitosan is present in the oral ingestible composition in the form of particles consisting of chitosan polysaccharide.

### Claim 31 (depends on 21)

The composition of claim 21, wherein the iron-binding glycoprotein and the chitosan are mixed throughout the oral ingestible composition.

### Claim 32 (depends on 21)

The composition of claim 21, further comprising an anti-inflammatory agent.

### Claim 33 (depends on 21)

The composition of claim 21, further comprising a phytobotanical anti-inflammatory agent.

### Claim 34 (depends on 21)

The composition of claim 21, wherein the oral ingestible composition further comprises a phytobotanical anti-inflammatory agent selected from the group consisting of curcumin, garlic, cinnamon, ginger, Roman chamomile, Echinacea, red clover, goldenseal, vitex (chaste tree), black pepper, and clove.

### Claim 35 (depends on 21)

The composition of claim 21, wherein the composition is produced by:
combining the iron-binding glycoprotein, the chitosan, and one or more additional ingredients of the oral ingestible composition, wherein, prior to the combining, the iron-binding glycoprotein and the chitosan are each present in a dry powder form; and
mixing the combined the iron-binding glycoprotein, the chitosan, and the one or more additional ingredients to thereby obtain the oral ingestible composition.

### Claim 36 (depends on 35)

The composition of claim 35, wherein the dry powder form of the chitosan comprises particles consisting of chitosan polysaccharide.

### Claim 37 (depends on 21)

The composition of claim 21, wherein:
the oral ingestible composition is in the form of a dough or gel;
the iron-binding glycoprotein is present in the oral ingestible composition in an amount of at least 0.05% by weight of the oral ingestible composition and up to 0.5% by weight of the oral ingestible composition;
chitosan, wherein the chitosan is present in the oral ingestible composition in an amount of at least 0.1% by weight of the oral ingestible composition and up to 2% by weight of the oral ingestible composition;
the iron-binding glycoprotein is ovotransferrin;
the chitosan is present in the oral ingestible composition in the form of particles consisting of chitosan polysaccharide;
the iron-binding glycoprotein and the chitosan are mixed throughout the oral ingestible composition.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the oral ingestible composition further comprises curcumin.

### Claim 39 (depends on 37)

The composition of claim 37, wherein the composition is produced by:
combining the iron-binding glycoprotein, the chitosan, and one or more additional ingredients of the oral ingestible composition, wherein, prior to the combining, the iron-binding glycoprotein and the chitosan are each present in a dry powder form, wherein the dry powder form of the chitosan comprises particles consisting of chitosan polysaccharide; and
mixing the combined the iron-binding glycoprotein, the chitosan, and the one or more additional ingredients to thereby obtain the oral ingestible composition.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the one or more additional ingredients comprises one or more of a bulking agent and curcumin.
